

Fiona C Brownfoot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3084566/publications.pdf>

Version: 2024-02-01

60
papers

1,607
citations

304368

22
h-index

315357

38
g-index

63
all docs

63
docs citations

63
times ranked

1628
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin as a prevention and treatment for preeclampsia: effects of soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 356.e1-356.e15.	0.7	156
2	Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. <i>Hypertension</i> , 2015, 66, 687-697.	1.3	154
3	Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. <i>The Cochrane Library</i> , 2013, , CD006764.	1.5	150
4	Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. <i>Hypertension</i> , 2017, 69, 457-468.	1.3	118
5	Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. , 2008, , CD006764.		70
6	Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. <i>Pregnancy Hypertension</i> , 2014, 4, 287-295.	0.6	52
7	EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble) Tj ETQq1 1 0.784314 rgBJ /Overl	1.3	50
8	Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment. <i>Scientific Reports</i> , 2017, 7, 1819.	1.6	49
9	Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 117.	0.9	47
10	Maternal intramuscular dexamethasone versus betamethasone before preterm birth (ASTEROID): a multicentre, double-blind, randomised controlled trial. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 769-780.	2.7	47
11	Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, S1157-S1170.	0.7	47
12	Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. <i>BMJ</i> , The, 2021, 374, n2103.	3.0	46
13	Sofalcone Upregulates the Nuclear Factor (Erythroid-Derived 2)-Like 2/Heme Oxygenase-1 Pathway, Reduces Soluble fms-Like Tyrosine Kinase-1, and Quenches Endothelial Dysfunction. <i>Hypertension</i> , 2015, 65, 855-862.	1.3	44
14	Knowledge Gaps and Emerging Research Areas in Intrauterine Growth Restriction-Associated Brain Injury. <i>Frontiers in Endocrinology</i> , 2019, 10, 188.	1.5	38
15	Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. <i>EBioMedicine</i> , 2019, 41, 636-648.	2.7	38
16	A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol. <i>BMJ Open</i> , 2019, 9, e025809.	0.8	34
17	Routine weighing to reduce excessive antenatal weight gain: a randomised controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 254-261.	1.1	33
18	Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. <i>Pregnancy Hypertension</i> , 2020, 20, 83-91.	0.6	33

#	ARTICLE	IF	CITATIONS
19	Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. <i>Hypertension</i> , 2015, 66, 1073-1081.	1.3	32
20	Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia. <i>PLoS ONE</i> , 2018, 13, e0188845.	1.1	31
21	Novel approaches to combat preeclampsia: from new drugs to innovative delivery. <i>Placenta</i> , 2020, 102, 10-16.	0.7	30
22	Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. <i>Hypertension</i> , 2017, 70, 1014-1024.	1.3	27
23	YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. <i>Molecular and Cellular Endocrinology</i> , 2015, 413, 202-208.	1.6	26
24	Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production1. <i>Biology of Reproduction</i> , 2016, 94, 59.	1.2	17
25	Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia. <i>Pregnancy Hypertension</i> , 2020, 22, 86-92.	0.6	15
26	Complex Atypical Hyperplasia of the Endometrium: Differences in Outcome Following Conservative Management of Pre- and Postmenopausal Women. <i>Reproductive Sciences</i> , 2014, 21, 1244-1248.	1.1	14
27	Women's opinions on being weighed at routine antenatal visits. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 263-270.	1.1	13
28	Predictive Value of the Signs and Symptoms Preceding Eclampsia. <i>Obstetrics and Gynecology</i> , 2019, 134, 677-684.	1.2	13
29	Personalized Anatomic Modeling for Noninvasive Fetal ECG: Methodology and Applications. <i>IEEE Transactions on Instrumentation and Measurement</i> , 2021, 70, 1-12.	2.4	13
30	Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta. <i>Placenta</i> , 2016, 48, 110-118.	0.7	12
31	Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. <i>Placenta</i> , 2020, 95, 78-83.	0.7	12
32	Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro. <i>Reproductive Sciences</i> , 2017, 24, 1245-1252.	1.1	11
33	Systematic review of areca (betel nut) use and adverse pregnancy outcomes. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 147, 292-300.	1.0	11
34	The incidence of hypertensive disorders of pregnancy following sperm donation in IVF: an Australian state-wide retrospective cohort study. <i>Human Reproduction</i> , 2019, 34, 2541-2548.	0.4	11
35	Prediction of adverse maternal outcomes in preeclampsia at term. <i>Pregnancy Hypertension</i> , 2019, 18, 75-81.	0.6	9
36	Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling. <i>Placenta</i> , 2019, 87, 53-57.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. <i>Placenta</i> , 2016, 48, 72-79.	0.7	9
38	sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?. <i>Pregnancy Hypertension</i> , 2017, 10, 18-21.	0.6	8
39	Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia. <i>Pregnancy Hypertension</i> , 2018, 13, 1-6.	0.6	8
40	Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 3821-3826.	0.7	7
41	Entropy Profiling for Detection of Fetal Arrhythmias in Short Length Fetal Heart Rate Recordings. , 2020, 2020, 621-624.		7
42	Loss of Akt increases soluble endoglin release from endothelial cells but not placenta. <i>Pregnancy Hypertension</i> , 2016, 6, 95-102.	0.6	6
43	EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia. <i>Pregnancy Hypertension</i> , 2018, 14, 115-120.	0.6	6
44	Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. <i>Scientific Reports</i> , 2021, 11, 16595.	1.6	5
45	Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling. <i>Placenta</i> , 2021, 114, 22-28.	0.7	5
46	Time to resolution of tubal ectopic pregnancy following methotrexate treatment: A retrospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0268741.	1.1	5
47	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. <i>EBioMedicine</i> , 2018, 29, 166-176.	2.7	4
48	High-dose compared with low-dose oxytocin for induction of labour of nulliparous women at term. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 32, 362-368.	0.7	4
49	Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction. <i>Journal of Clinical Medicine</i> , 2022, 11, 901.	1.0	4
50	Detection of fetal arrhythmias in non-invasive fetal ECG recordings using data-driven entropy profiling. <i>Physiological Measurement</i> , 2022, , .	1.2	3
51	Growth trajectory of preterm small-for-gestational-age neonates. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 8400-8406.	0.7	2
52	Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome. <i>Pregnancy Hypertension</i> , 2018, 14, 125-130.	0.6	1
53	Nicotinamide and its effects on endothelial dysfunction and secretion of antiangiogenic factors by primary human placental cells and tissues. <i>Placenta</i> , 2021, 109, 28-31.	0.7	1
54	Uterine artery embolisation associated with greater need for reintervention than surgical treatment for symptomatic uterine fibroids; quality of life similar though study underpowered. <i>Evidence-Based Medicine</i> , 2012, 17, 87-88.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Peptides do not prevent cleavage of endoglin to produce soluble endoglin. <i>Pregnancy Hypertension</i> , 2014, 4, 255-258.	0.6	0
56	Re: Pregnancy-associated plasma protein-A is positively correlated with first-trimester skin microvascular reactivity. C. Iacobaeus, T. Kahan, G. Järneskog, K. Bremme, E. Andolf and M. Thorsell. <i>Ultrasound Obstet Gynecol</i> 2018; 51: 361-367. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 305-305.	0.9	0
57	Accuracy of clinical suspicion of growth restriction at term despite a normal growth ultrasound: A retrospective cohort study. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 568-573.	0.4	0
58	Uncovering the Molecular Cause of Preeclampsia—The Role of Glutathionylation of the Na ⁺ /K ⁺ ATPase Transporter. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2830-e2832.	1.8	0
59	Management of late preterm preeclampsia: a comparison of maternal and fetal indications for delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, , 1-10.	0.7	0
60	Evaluation of Mesh and Sensor Resolution for Finite Element Modeling of Non-Invasive Fetal ECG Signals. , 2021, 2021, 4134-4138.		0